GLP-1 Addiction Treatment: What the Research Says About Semaglutide and Alcohol Cravings

The Surprising Connection: Weight Loss Drugs and Addiction

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. GLP-1 receptor agonists (GLP-1 RAs) mimic this hormone to lower blood sugar and reduce appetite. But researchers have discovered that GLP-1 receptors are not limited to the digestive system — they are also found throughout the brain, including in regions that control reward and motivation.¹

These brain regions — the ventral tegmental area (VTA), nucleus accumbens, and prefrontal cortex — form the core of what scientists call the mesolimbic reward pathway. This is the same circuit involved in both food cravings and addiction. When alcohol or other substances activate this pathway, they trigger a surge of dopamine (a chemical messenger associated with pleasure), which reinforces the behavior.²

Anecdotal reports began emerging on Reddit and social media from people taking GLP-1 drugs for weight loss who noticed something unexpected: their desire to drink alcohol had dropped sharply. These patient accounts caught the attention of addiction researchers, who saw a biologically plausible mechanism worth investigating.

The GLP-1 addiction treatment connection is still new, but it has moved rapidly from anecdote to clinical trial in just a few years.

What Research Shows

Several large-scale studies have now examined GLP-1 drugs and alcohol use disorder (AUD), and the results are striking.

A retrospective cohort study analyzing electronic health records from 136 US health systems found that patients prescribed a GLP-1 receptor agonist had approximately 40% lower rates of opioid overdose compared to those not taking the drug (adjusted incidence rate ratio, 0.60; 95% CI, 0.43-0.83).³ While this study focused on opioids, it pointed toward a broader relationship between GLP-1 drugs and substance use risk.

A separate cohort study with more than eight years of median follow-up found that individuals using GLP-1 agonists — especially semaglutide — were at significantly lower risk of alcohol-related hospitalizations compared to periods when they were not taking the drug.⁴ Among patients with both AUD and comorbid obesity or type 2 diabetes, semaglutide was associated with a greater reduction in hospitalization risk than any of the three currently FDA-approved medications for AUD.

Research suggests the effect may extend beyond alcohol. Preclinical animal studies and early human data have shown semaglutide and related GLP-1 drugs may also reduce cravings for nicotine and opioids, pointing to a shared mechanism across addictive substances.³

The JAMA Psychiatry Trial

The most rigorous evidence to date on GLP-1 addiction treatment comes from a phase 2 randomized clinical trial published in JAMA Psychiatry in February 2025. The trial was conducted at the University of North Carolina-Chapel Hill School of Medicine and led by researcher Christian S. Hendershot and colleagues.⁵

The trial enrolled 48 non-treatment-seeking adults with AUD over a nine-week period. Participants were randomized to receive once-weekly subcutaneous (under-the-skin) injections of semaglutide or a placebo. The semaglutide group started at 0.25 mg per week, titrating up to 1.0 mg over the study period.

The key findings were:

• Semaglutide significantly reduced the amount of alcohol consumed in a post-treatment laboratory self-administration task (medium to large effect sizes, p = .01).

• Peak breath alcohol concentration was also lower in the semaglutide group (p = .03).

• Over nine weeks of treatment, semaglutide significantly reduced weekly alcohol craving compared to placebo.

• Drinks per drinking day and heavy drinking frequency both declined more in the semaglutide group.

This was a small, early-phase trial, which means it was designed to test whether semaglutide for alcohol use disorder has a signal worth pursuing — not to prove definitive effectiveness. Larger phase 3 trials are now underway.⁵

How It May Work

To understand why a diabetes drug might reduce alcohol cravings, it helps to think about how addiction works in the brain.

When you drink alcohol, it triggers a release of dopamine in the nucleus accumbens — a small structure deep in the brain sometimes called the brain's reward center. This dopamine surge creates feelings of pleasure and reinforces the desire to drink again. Over time, the brain begins to anticipate this reward, generating cravings even before any alcohol is consumed.

GLP-1 receptors are expressed directly in and around the nucleus accumbens and the VTA, which is the region that sends dopamine signals to it.² Research suggests that when GLP-1 receptor agonists activate these receptors, they modulate — or fine-tune — how much dopamine is released in response to rewarding substances.

A key insight from preclinical research published in PMC and NIH-affiliated journals is that GLP-1 receptor agonists appear to selectively dampen reward-driven dopamine spikes without broadly suppressing dopamine function.² Think of it like a volume knob on a stereo: the drug may turn down the loudness of the reward signal that alcohol creates, making drinking feel less pleasurable and reducing the craving to do it again.

This GLP-1 dopamine reward pathway effect parallels the same mechanism that reduces food noise — the intrusive, persistent thoughts about food that many patients on these drugs report disappearing. The reward circuitry for food and alcohol overlaps significantly, which may explain why a single drug can appear to affect both.

It is worth noting that depression symptoms and alcohol use disorder often co-occur, and both involve dysregulation of overlapping brain circuits. Researchers are investigating whether GLP-1 drugs may have effects on mood as well, though more study is needed.

Why This Matters

The case for new alcohol use disorder treatments is urgent. According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), AUD affects tens of millions of Americans and is linked to significant health consequences, including liver disease, cardiovascular disease, and increased cancer risk.⁶

Currently, only three FDA-approved medications exist for treating alcohol use disorder: naltrexone (approved 1994), acamprosate (approved 2004), and disulfiram (approved 1949).⁶ Despite decades of availability, these medications are prescribed to only a small fraction of people with AUD. Stigma, side effects, adherence challenges, and limited awareness all contribute to the treatment gap.

The potential of semaglutide alcohol use disorder treatment is significant for several reasons:

• Semaglutide is already widely prescribed and has a well-understood safety profile for its approved uses.

• Unlike disulfiram, which works by making drinking feel physically aversive, semaglutide may work by reducing the desire to drink in the first place.

• Patients with AUD often have comorbid obesity or type 2 diabetes — two conditions for which GLP-1 drugs are already approved — creating a realistic path for dual-purpose prescribing under medical supervision.

• Early real-world data suggest it may outperform existing AUD medications in certain populations.⁴

If larger trials confirm these results, GLP-1 drugs could represent the most meaningful advance in addiction pharmacology in decades.

Where the Research Stands

It is important to be clear about what the current evidence does and does not show.

The Ozempic alcohol cravings data are promising, but the field is still early. The landmark JAMA Psychiatry trial involved just 48 participants over nine weeks. Observational studies, while large, cannot fully eliminate confounding factors — meaning other differences between patients taking GLP-1 drugs and those who are not may partly explain the findings.

Phase 3 trials (larger, longer studies designed to confirm effectiveness) are currently underway. Until those results are available, semaglutide for GLP-1 substance abuse treatment remains investigational and is not FDA-approved for this indication.⁵

This means you should not start or modify a GLP-1 medication on your own with the goal of reducing alcohol use. These are prescription medications with real side effects — including nausea, vomiting, and rarely more serious complications — that require careful medical supervision and dosing.

The research is genuinely exciting, and addiction specialists have described the early data as very promising. But excitement about emerging science is different from established, approved treatment. The two stages should not be conflated.

When to See a Doctor

If you are concerned about your alcohol use, speaking with a healthcare provider is the most important step you can take. You may want to raise questions about GLP-1 drugs with your doctor if:

• You have been diagnosed with alcohol use disorder and are not responding to existing treatments.

• You have AUD alongside obesity or type 2 diabetes, conditions for which GLP-1 drugs are already approved.

• You have noticed changes in your alcohol cravings after starting a GLP-1 medication for another reason.

• You are interested in participating in clinical trials for semaglutide and AUD.

Warning signs that warrant prompt medical attention include drinking that interferes with daily functioning, withdrawal symptoms when you stop drinking (such as shaking, sweating, or seizures), and thoughts of harming yourself or others. Withdrawal from alcohol can be medically dangerous and should always be managed with professional support.

Do not stop or start any prescription medication — including GLP-1 drugs — without guidance from a qualified healthcare provider.

Conclusion

GLP-1 receptor agonists represent a genuinely novel avenue for alcohol use disorder treatment, backed by increasingly rigorous evidence. The 2025 JAMA Psychiatry trial showed meaningful reductions in alcohol consumption and cravings with semaglutide, and large real-world studies have found lower rates of alcohol-related hospitalizations in GLP-1 users. The likely mechanism — modulation of the brain's dopamine reward pathway — makes biological sense and may explain reports of reduced cravings in patients already on these drugs.

That said, GLP-1 addiction treatment remains under investigation. It is not yet FDA-approved for alcohol use disorder, and larger confirmatory trials are still needed. If you are struggling with alcohol use, the best step is a conversation with your doctor about the full range of evidence-based treatment options available today.

References

1. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. https://pubmed.ncbi.nlm.nih.gov/39937469/

2. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. PMC/MDPI. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC12372146/

3. Mapping the effectiveness and risks of GLP-1 receptor agonists. PubMed. 2025. https://pubmed.ncbi.nlm.nih.gov/39833406/

4. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11561716/

5. Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. February 2025. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811

6. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Medications Development Program. NIH. https://www.niaaa.nih.gov/medications-development-program

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. The information presented here should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have concerns about your health, please seek immediate medical attention.